| pubmed-article:15201989 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:15201989 | lifeskim:mentions | umls-concept:C0007634 | lld:lifeskim |
| pubmed-article:15201989 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:15201989 | lifeskim:mentions | umls-concept:C0555198 | lld:lifeskim |
| pubmed-article:15201989 | lifeskim:mentions | umls-concept:C0754515 | lld:lifeskim |
| pubmed-article:15201989 | lifeskim:mentions | umls-concept:C0010656 | lld:lifeskim |
| pubmed-article:15201989 | lifeskim:mentions | umls-concept:C0086860 | lld:lifeskim |
| pubmed-article:15201989 | lifeskim:mentions | umls-concept:C1705822 | lld:lifeskim |
| pubmed-article:15201989 | lifeskim:mentions | umls-concept:C0348011 | lld:lifeskim |
| pubmed-article:15201989 | lifeskim:mentions | umls-concept:C0205195 | lld:lifeskim |
| pubmed-article:15201989 | lifeskim:mentions | umls-concept:C0439858 | lld:lifeskim |
| pubmed-article:15201989 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:15201989 | pubmed:dateCreated | 2004-6-17 | lld:pubmed |
| pubmed-article:15201989 | pubmed:abstractText | Recently, we have reported the therapeutic efficacy of delivering initiator caspase (caspase-8) or executioner active caspase (rev-caspase-6) to telomerase-positive malignant glioma cells using the human telomerase reverse transcriptase (hTERT) gene promoter system (hTERT/caspase-8 or hTERT/rev-caspase-6). In the present study, we investigated if conventional treatments for malignant gliomas augment the efficacy of the hTERT/caspase therapy. First, we demonstrated that hTERT/rev-caspase-6 exhibited a greater ability to induce apoptosis in malignant glioma U87-MG and U373-MG cells than hTERT/caspase-8. Next, as conventional treatments to combine with hTERT/rev-caspase-6, apoptosis-inducing agents [cisplatin (CDDP), paclitaxel (PTX), and BCNU] and non-apoptosis-inducing therapies [temozolomide (TMZ) and gamma-irradiation (IR)] were used. Combination of hTERT/rev-caspase-6 gene therapy with PTX yielded a dose-dependent additive effect, while CDDP and BCNU had additive effect only when tumor cells were treated at IC75 of each agent. A decline in the combination effect of CDDP and BCNU at IC50 was due to decreased activity of telomerase in treated tumor cells prior to the hTERT/rev-caspase-6 transfer. On the other hand, TMZ or IR had no significant additive effect on induction of apoptosis. These results suggest that agents, which induce apoptosis without inhibiting telomerase activity are a promising counterpart to combine with hTERT/rev-caspase-6 therapy for the management of malignant gliomas. | lld:pubmed |
| pubmed-article:15201989 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15201989 | pubmed:language | eng | lld:pubmed |
| pubmed-article:15201989 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15201989 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:15201989 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15201989 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15201989 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15201989 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15201989 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15201989 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15201989 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15201989 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15201989 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:15201989 | pubmed:month | Jul | lld:pubmed |
| pubmed-article:15201989 | pubmed:issn | 1019-6439 | lld:pubmed |
| pubmed-article:15201989 | pubmed:author | pubmed-author:HirohataSatos... | lld:pubmed |
| pubmed-article:15201989 | pubmed:author | pubmed-author:KomataTadashi... | lld:pubmed |
| pubmed-article:15201989 | pubmed:author | pubmed-author:KanzawaTakaoT | lld:pubmed |
| pubmed-article:15201989 | pubmed:author | pubmed-author:KondoYasukoY | lld:pubmed |
| pubmed-article:15201989 | pubmed:author | pubmed-author:KondoSeijiS | lld:pubmed |
| pubmed-article:15201989 | pubmed:author | pubmed-author:KyoSatoruS | lld:pubmed |
| pubmed-article:15201989 | pubmed:author | pubmed-author:TakeuchiHayat... | lld:pubmed |
| pubmed-article:15201989 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:15201989 | pubmed:volume | 25 | lld:pubmed |
| pubmed-article:15201989 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:15201989 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:15201989 | pubmed:pagination | 57-63 | lld:pubmed |
| pubmed-article:15201989 | pubmed:dateRevised | 2008-11-21 | lld:pubmed |
| pubmed-article:15201989 | pubmed:meshHeading | pubmed-meshheading:15201989... | lld:pubmed |
| pubmed-article:15201989 | pubmed:meshHeading | pubmed-meshheading:15201989... | lld:pubmed |
| pubmed-article:15201989 | pubmed:meshHeading | pubmed-meshheading:15201989... | lld:pubmed |
| pubmed-article:15201989 | pubmed:meshHeading | pubmed-meshheading:15201989... | lld:pubmed |
| pubmed-article:15201989 | pubmed:meshHeading | pubmed-meshheading:15201989... | lld:pubmed |
| pubmed-article:15201989 | pubmed:meshHeading | pubmed-meshheading:15201989... | lld:pubmed |
| pubmed-article:15201989 | pubmed:meshHeading | pubmed-meshheading:15201989... | lld:pubmed |
| pubmed-article:15201989 | pubmed:meshHeading | pubmed-meshheading:15201989... | lld:pubmed |
| pubmed-article:15201989 | pubmed:meshHeading | pubmed-meshheading:15201989... | lld:pubmed |
| pubmed-article:15201989 | pubmed:meshHeading | pubmed-meshheading:15201989... | lld:pubmed |
| pubmed-article:15201989 | pubmed:meshHeading | pubmed-meshheading:15201989... | lld:pubmed |
| pubmed-article:15201989 | pubmed:meshHeading | pubmed-meshheading:15201989... | lld:pubmed |
| pubmed-article:15201989 | pubmed:meshHeading | pubmed-meshheading:15201989... | lld:pubmed |
| pubmed-article:15201989 | pubmed:meshHeading | pubmed-meshheading:15201989... | lld:pubmed |
| pubmed-article:15201989 | pubmed:meshHeading | pubmed-meshheading:15201989... | lld:pubmed |
| pubmed-article:15201989 | pubmed:year | 2004 | lld:pubmed |
| pubmed-article:15201989 | pubmed:articleTitle | Combination of caspase transfer using the human telomerase reverse transcriptase promoter and conventional therapies for malignant glioma cells. | lld:pubmed |
| pubmed-article:15201989 | pubmed:affiliation | Department of Neurosurgery, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA. | lld:pubmed |
| pubmed-article:15201989 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:15201989 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| pubmed-article:15201989 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| entrez-gene:7015 | entrezgene:pubmed | pubmed-article:15201989 | lld:entrezgene |
| http://linkedlifedata.com/r... | entrezgene:pubmed | pubmed-article:15201989 | lld:entrezgene |
| lhgdn:association:56645 | lhgdn:found_in | pubmed-article:15201989 | lld:lhgdn |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15201989 | lld:pubmed |
